Ask Warren

Hans Biomed

042520 · KOSDAQ · ₩042520 · 한스바이오메드

₩17,030▼ ₩500 (2.85%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Revenue₩24B₩22B₩14B₩30B₩20B₩21B₩21B₩20B
Cost of sales₩13B₩8B₩6B₩11B₩6.9B₩7.8B₩6.8B₩7.9B
Gross profit₩11B₩14B₩7.7B₩19B₩13B₩13B₩14B₩12B
Operating income−₩27B₩41M−₩1B₩2.1B−₩1.1B₩654M₩1.8B−₩749M
Net income−₩29B−₩4.2B−₩1.1B₩1.9B−₩7.8B₩400M₩1.6B−₩2B
Net income to shareholders−₩28B−₩3.3B−₩2.5B₩2.1B−₩6.2B₩94M₩767M−₩1.8B

Balance sheet

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Total assets₩126B₩130B₩129B₩141B₩122B₩125B₩121B₩119B
Current assets₩56B₩61B₩58B₩71B₩50B₩50B₩48B₩50B
Cash and equivalents₩8.1B₩10B₩12B₩16B₩7.3B₩8B₩7.7B₩5.5B
Total liabilities₩93B₩68B₩63B₩70B₩55B₩51B₩48B₩55B
Current liabilities₩81B₩58B₩54B₩61B₩50B₩46B₩44B₩50B
Borrowings₩41B₩41B₩41B₩41B₩37B₩31B₩30B₩34B
Total equity₩34B₩62B₩65B₩71B₩67B₩74B₩73B₩64B
Shareholders' equity₩34B₩62B₩65B₩71B₩67B₩74B₩72B₩64B

Cash flow

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Cash from operations₩1.2B−₩924M₩25B−₩25B−₩749M₩159M₩3.8B−₩1.4B
Capital spending₩449M₩528M−₩156M₩880M₩618M₩700M₩948M₩329M
Free cash flow₩757M−₩1.5B₩25B−₩26B−₩1.4B−₩540M₩2.8B−₩1.8B

Consolidated where available. Amounts in won.

Also known as: Hans Biomed / 한스바이오메드 / 042520 / KRX:042520

Source: KRX statistical information